title: The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring.
abstract: BACKGROUND
  The increasing use of tyrosine kinase inhibitor therapy outside of the context of the clinical trial for treatment of advanced thyroid cancer has highlighted the need for a systematic approach to the clinical application of these agents in order to improve patient safety and monitoring promote consistency among providers, and ensure compliance with both institutional and industry standards.
  
  
  METHODS
  We reviewed professional thyroid cancer guidelines, the National Comprehensive Cancer Network task force reports, American Society of Clinical Oncology safety standards, review articles, and clinical trials published within the past 10 yr and also included relevant older studies.
  
  
  CONCLUSIONS
  Review of available published data and the collective experience prescribing tyrosine kinase inhibitors at The University of Texas MD Anderson Cancer Center have highlighted the need for a systematic, comprehensive, and uniform approach to managing these patients. This paper discusses the approach adopted by the Department of Endocrine Neoplasia at the MD Anderson Cancer Center and illustrates practice patterns, experience, and our standardized approach related to prescribing commercially available tyrosine kinase inhibitors outside of the context of a clinical trial for patients with advanced thyroid cancer.
authors.affiliation: Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Baylor College of Medicine, Houston, Texas 77030, USA.
authors.forename: Aubrey A
authors.initials: AA
authors.lastname: Carhill
authors.forename: Maria E
authors.initials: ME
authors.lastname: Cabanillas
authors.forename: Camilo
authors.initials: C
authors.lastname: Jimenez
authors.forename: Steven G
authors.initials: SG
authors.lastname: Waguespack
authors.forename: Mouhammed A
authors.initials: MA
authors.lastname: Habra
authors.forename: Mimi
authors.initials: M
authors.lastname: Hu
authors.forename: Anita
authors.initials: A
authors.lastname: Ying
authors.forename: Rena
authors.initials: R
authors.lastname: Vassilopoulou-Sellin
authors.forename: Robert F
authors.initials: RF
authors.lastname: Gagel
authors.forename: Steven I
authors.initials: SI
authors.lastname: Sherman
authors.forename: Naifa L
authors.initials: NL
authors.lastname: Busaidy
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems / Q000592:standards; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy*; D006801:Humans; D008991:Monitoring, Physiologic / Q000379:methods / Q000592:standards*; D061214:Patient Safety / Q000592:standards*; D017410:Practice Guidelines as Topic; D011364:Professional Practice / Q000592:standards; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D013964:Thyroid Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases